Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von pharmaphorum

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
14:59Bayer trial combines two top drugs for kidney disease
13:58Digital health firm Omada Health prices $150m IPO
12:59AZ claims EU approval for new Calquence regimens in CLL
10:59Wockhardt has high hopes for novel antibiotic Zaynich
DoNew auction for 23andMe sought with $305m bid from ex-CEO
DoHas mRNA delivered a breakthrough in quest for HIV cure?
DoNHS cleared to use Novo Nordisk's long-acting growth hormone
DoMHRA advises contraception for women taking 'skinny jabs'
DoEU: Trials should include pregnant subjects where possible
DoNeuralink raises $650m to widen use of brain implants
MiAscletis says oral acne drug shows "exceptional efficacy"
MiHims & Hers buys Zava to form European beachhead
MiMSD rumoured to be eyeing $3bn+ MoonLake takeover
MiASCO 25: Sanofi hopes on-body delivery will boost Sarclisa
MiASCO 25: J&J combo pill may see wider use in prostate cancer
DiAmid staff cuts, FDA looks to AI to 'optimise' reviews
DiASCO 25: Enhertu bids for earlier use in HER2+ breast cancer
MoConsolidation in psychedelics as atai pairs with Beckley
MoBioNTech flips its cancer bispecific to BMS for a big profit
MoASCO 25: AZ pitches upfront oral SERD use in breast cancer
Mo23andMe founder isn't giving up her bid to regain control
MoSanofi draws up $9.1bn plan to buy Blueprint Medicines
30.05.Summit shrugs off survival miss with its VEGF bispecific
30.05.Astellas adds to claudin clout with $1.3bn+ Evopoint deal
30.05.Roche builds case for MS drug with two-year efficacy data